文献速递炎症性肠病

男性受孕前使用抗肿瘤坏死因子-α药物治疗后所育子女的出生结局

Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-α Agents Before Conception.
PubMed 文献 · Am J Gastroenterol · 2016-09-13

基于丹麦全国登记数据,纳入2007年1月1日至2013年间所有活产单胎,暴露组为受孕前3个月内使用抗肿瘤坏死因子-α(TNF-α)药物的男性所育子女(N=372),非暴露组为受孕前未使用该类药物男性所育子女(N=399,498)。调整后先天畸形和早产风险接近1,小于胎龄儿(SGA)调整OR为1.70(95%CI 0.94-3.09);作者认为总体结果令人安心,但SGA结果应谨慎解读。

要点

  • 男性受孕前3个月内使用抗TNF-α药物与先天畸形、早产风险接近1相关。
  • SGA调整OR为1.70(95%CI 0.94-3.09),风险升高但未达统计学显著。
  • 按疾病分层后,炎症性肠病和风湿/皮肤病父亲中均未见CAs或SGA风险增加。

核心结论

  • 作者认为,男性受孕前使用抗TNF-α药物的安全性总体令人安心;但SGA结果应谨慎解读,因发现风险增加但未达统计学显著。

研究设计与样本

  • 基于丹麦全国健康登记数据的全国性队列研究,纳入2007年1月1日至2013年间所有活产单胎。
  • 暴露组为受孕前3个月内使用抗TNF-α药物的男性所育子女(N=372),非暴露组为受孕前未使用该类药物男性所育子女(N=399,498)。
  • 结局为先天畸形(CAs)、早产和小于胎龄儿(SGA),调整多个协变量并考虑父亲基础疾病和合并用药。

主要发现

  • CAs和早产的调整风险接近1。
  • SGA的调整OR为1.70(95%CI 0.94-3.09)。
  • 限制于炎症性肠病父亲的分析中,CAs或SGA风险未见增加,早产的调整OR为1.42(95%CI 0.52-3.86)。
  • 限制于风湿/皮肤病父亲的分析中,CAs或早产风险未见增加,SGA的调整OR为1.70(95%CI 0.74-3.89)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The safety of paternal use of anti-tumor necrosis factor-α (TNF-α) agents immediately prior to conception is practically unknown. On the basis of nationwide data from Danish health registries, we examined the association between paternal use of anti-TNF-α agents within 3 months before conception and adverse birth outcomes. METHODS: This nationwide cohort study is based on data from all women who had a live born singleton child in Denmark from 1 January 2007 through 2013. Children fathered by men treated with anti-TNF-α agents within three months before conception constituted the exposed cohort (N=372), and children fathered by men not treated before conception constituted the unexposed cohort (N=399,498). The outcomes were congenital abnormalities (CAs), preterm birth, and small for gestational age (SGA). We adjusted for multiple covariates, and considered paternal underlying disease and concomitant medication. RESULTS: The adjusted risks of CAs and preterm birth were close to unity, and the adjusted odds ratio (OR) for SGA was 1.70 (95% confidence interval (CI): 0.94-3.09). Restricting our analysis to fathers with inflammatory bowel disease, we found no increased risk of CAs or SGA, and the adjusted OR for pretem birth was 1.42 (95% CI: 0.52-3.86). Restricting our analysis to fathers with rheumatologic/dermatological diseases, we found no increased risk of CAs or preterm birth, and the adjusted OR for SGA was 1.70 (95% CI: 0.74-3.89). CONCLUSIONS: Our results are overall reassuring regarding the safety of paternal preconceptional use of anti-TNF-α agents. The result regarding SGA should, however, be interpreted with caution as we found an increased risk, although not significantly increased.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Larsen MD, Friedman S, Magnussen B, et al. Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-α Agents Before Conception. Am J Gastroenterol. 2016. PMID: 27619836. doi:10.1038/ajg.2016.405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。